Genotype | Dhfr Locus 59 | Chr1SNP | Chr7SNP | Chr8SNP | Chr9SNP | Chr13SNP |
---|
Status | XYa | Polarb | XYa | Polarb | XYa | Polarb | XYa | Polarb | XYa | Polarb | XYa | Polarb |
---|
Not Infected
| 127 | 137 | 77 | 104 | 92 | 92 | 70 | 28 | 66 | 95 | 92 | 93 |
Inf. w/Allele 1
| 25c | 63 | 19 | 28 | 48 | 60 | 141 | 147 | 4 | 127 | 47 | 108 |
Inf. w/Allele 2
| 25d | 37 | 46 | 166 | 102 | 152 | 42 | 27 | 44 | 71 | 77 | 83 |
Mixed Infection
| 87 | 17 | 215 | 24 | 115 | 28 | 41 | 34 | 243 | 36 | 141 | 41 |
Uncertain
e
| - | 10 | - | 35 | - | 25 | - | 58 | - | 28 | - | 32 |
Total Samples
f
|
264
|
357
|
357
|
294
|
357
|
357
|
Reclassified
g
|
86
|
226
|
96
|
76
|
237
|
126
|
- aCounts determined based on the conventional threshold of 3× standard deviations above the mean - see Figure 4A.
- bCounts determined after applying polar transformation method - see Figure 4C.
- cFor Dhfr locus 59, allele 1 is associated with drug sensitivity.
- dFor Dhfr locus 59, allele 2 is associated with drug resistance.
- eNo samples are considered uncertain by conventional (XY) methods, as confidence intervals are not considered.
- fThe total number of samples genotyped at each locus.
- gThe number of samples whose allele calls differed between the XY and polar transformation methods.